Literature DB >> 16959607

Mutant p53 gain of function: the NF-Y connection.

Melissa J Peart1, Carol Prives.   

Abstract

The molecular mechanisms underlying mutant p53 gain of function are becoming increasingly complex. In this issue of Cancer Cell, Di Agostino et al. identify the heterotrimeric transcription factor NF-Y as an interacting partner of mutant p53. They show that mutant p53/NF-Y complexes bind to NF-Y target promoters and recruit p300 in response to DNA damage, resulting in aberrant transactivation of NF-Y target genes and cell cycle deregulation. These data thereby implicate transcriptional activation by mutant p53 as a key mechanism responsible for its oncogenic activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959607     DOI: 10.1016/j.ccr.2006.08.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  18 in total

1.  Differential regulation of p53 target genes: it's (core promoter) elementary.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

Review 2.  NF-Y (CBF) regulation in specific cell types and mouse models.

Authors:  Sankar N Maity
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2016-11-02       Impact factor: 4.490

3.  A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest.

Authors:  Lai Xu; Abdel G Elkahloun; Fabio Candotti; Andrzej Grajkowski; Serge L Beaucage; Emanuel F Petricoin; Valerie Calvert; Hartmut Juhl; Frederick Mills; Karen Mason; Neal Shastri; Josh Chik; Cynthia Xu; Amy S Rosenberg
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

4.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

Review 5.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

6.  A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.

Authors:  Xiaoping Huang; Ying Zhang; Yaqiong Tang; Napoleon Butler; Jungeun Kim; Fadila Guessous; David Schiff; James Mandell; Roger Abounader
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

Review 7.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

8.  Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.

Authors:  Wensheng Yan; Gang Liu; Ariane Scoumanne; Xinbin Chen
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells.

Authors:  Di Yang; Yitao Qi; Qian Chen; Zhiqin Wang; Xi Jin; Jie Gao; Juanling Fu; Xilong Xiao; Zongcan Zhou
Journal:  Mol Cell Biochem       Date:  2007-05-26       Impact factor: 3.396

10.  Genetic and biochemical alterations in non-small cell lung cancer.

Authors:  Jackie L Johnson; Smitha Pillai; Srikumar P Chellappan
Journal:  Biochem Res Int       Date:  2012-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.